A Research Guide for
Narcolepsy

Narcolepsy Type 1 accounts for roughly two-thirds of all narcolepsy cases. It is defined by:

• Excessive daytime sleepiness plus definite cataplexy, confirmed by MSLT criteria (mean sleep latency ≤8 minutes and ≥2 sleep-onset REM periods), OR
• Low cerebrospinal fluid (CSF) hypocretin-1 (orexin-A) levels — below 110 pg/mL or less than one-third of normal values.

The underlying cause is well established: an autoimmune process destroys 85–95% of the roughly 70,000 orexin-producing neurons in the lateral hypothalamus. This loss is permanent in most cases. The HLA-DQB1*06:02 allele is present in up to 98% of Type 1 patients, strongly supporting the autoimmune mechanism.

Type 1 patients experience the full spectrum of symptoms, including cataplexy, and generally have more severe sleep-wake instability than Type 2 patients.

Narcolepsy Type 2 accounts for roughly one-third of cases. It is defined by:

• Excessive daytime sleepiness
• MSLT criteria met (mean sleep latency ≤8 minutes and ≥2 sleep-onset REM periods)
• No cataplexy, and CSF hypocretin-1 levels are either normal or have not been measured

The underlying mechanism is less clear. Current hypotheses include partial loss of orexin neurons (not enough to cause cataplexy but sufficient to disrupt wakefulness), impaired orexin receptor signaling, or other mechanisms not yet identified. About half of Type 2 patients carry the HLA-DQB1*06:02 allele, suggesting some share the autoimmune biology of Type 1 but with a milder degree of orexin neuron loss.

Important: some patients initially diagnosed with Type 2 later develop cataplexy and are reclassified as Type 1. Ongoing monitoring is appropriate.

Both types are treated with wakefulness-promoting agents for excessive daytime sleepiness. The key difference is that Type 1 patients also need treatment specifically targeting cataplexy — sodium oxybate, pitolisant, or certain antidepressants. The emerging orexin receptor agonists have shown the most dramatic benefits in Type 1, where the orexin deficiency is most profound, but alixorexton has also shown positive results in Type 2 trials.

Orexin (also called hypocretin) is a neuropeptide produced by a small cluster of roughly 70,000 neurons in the lateral hypothalamus. Despite their small number, these neurons project widely throughout the brain and play a critical role in stabilizing the boundaries between wakefulness, NREM sleep, and REM sleep. When orexin signaling is intact, transitions between these states are orderly. When orexin is absent, the boundaries collapse — REM sleep intrudes into wakefulness (causing cataplexy, sleep paralysis, and hallucinations), and wakefulness cannot be sustained (causing excessive daytime sleepiness).

Orexin also influences appetite, metabolism, autonomic function, and reward pathways, which is why narcolepsy affects more than just sleep.

Research led by Emmanuel Mignot at Stanford and others has established that narcolepsy Type 1 is an autoimmune disorder. The evidence includes:

• Near-complete loss of orexin neurons: Postmortem studies show 85–95% of orexin-producing neurons are destroyed in Type 1 patients.
• Genetic susceptibility: Up to 98% of Type 1 patients carry HLA-DQB1*06:02, an immune system gene variant. This is one of the strongest HLA-disease associations known.
• T-cell reactivity: Studies have found autoreactive CD4+ and CD8+ T cells that target orexin neuron antigens in narcolepsy patients.
• Environmental triggers: Epidemiological links to H1N1 influenza infection, streptococcal infections, and the Pandemrix H1N1 vaccine (which used the AS03 adjuvant) support an immune trigger model.

This autoimmune understanding has opened two therapeutic directions: replacing the missing orexin signal (orexin receptor agonists) and intervening in the autoimmune process early to prevent neuron loss (immunotherapy in early-onset disease).

HLA-DQB1*06:02 is present in roughly 12–38% of the general population (varying by ethnicity) but in up to 98% of narcolepsy Type 1 patients. Testing for it can be useful in certain diagnostic situations — if the allele is absent, narcolepsy Type 1 is very unlikely. However, its presence does not confirm narcolepsy, because most carriers never develop the disease. It is a susceptibility marker, not a diagnostic test.

When evaluating any treatment claim, ask these questions:

• Has it been tested in narcolepsy specifically, in a controlled clinical trial?
• Is it published in a peer-reviewed journal, or is it an anecdote from a forum?
• Does anyone with no financial stake in it recommend it?
• Could it interfere with current medications (especially sodium oxybate, which has significant drug interactions)?
• Are sleep medicine specialists at major centers using it?

Be especially cautious of anyone who claims to “cure” narcolepsy, sells the product they recommend, or suggests stopping prescribed medication in favor of supplements or alternative protocols. Narcolepsy is a lifelong neurological condition caused by the permanent loss of specific brain cells — no supplement can regenerate them.

The standard diagnostic pathway involves:

• Clinical history: A detailed history of symptoms — when the sleepiness started, whether naps are refreshing, presence of cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep. Sleep diaries and the Epworth Sleepiness Scale (ESS) help quantify sleepiness.
• Exclusion of other causes: Other conditions that cause excessive sleepiness must be ruled out: obstructive sleep apnea, insufficient sleep syndrome, medication effects, thyroid disorders, depression, and other medical conditions.
• Overnight polysomnogram (PSG): An overnight sleep study that monitors brain waves, eye movements, muscle activity, heart rhythm, and breathing. This primarily rules out other sleep disorders (especially sleep apnea) and serves as the prerequisite for the MSLT the following day.
• Multiple Sleep Latency Test (MSLT): Performed the day after the PSG. The patient is given four or five 20-minute nap opportunities at two-hour intervals. Narcolepsy criteria: mean sleep latency of 8 minutes or less, with two or more sleep-onset REM periods (SOREMPs). A SOREMP on the preceding night’s PSG can count as one of the two.

A lumbar puncture (spinal tap) to measure CSF hypocretin-1 (orexin-A) levels can definitively confirm narcolepsy Type 1. A level below 110 pg/mL, or less than one-third of normal mean values, is diagnostic — regardless of other test results. This test is not routinely performed as a first-line investigation because it is invasive, but it is valuable when:

• The MSLT results are ambiguous or borderline
• The patient is taking medications that affect REM sleep and cannot safely discontinue them for the MSLT
• Cataplexy is uncertain or atypical
• A definitive diagnosis is needed for disability, insurance, or medication access purposes

CSF hypocretin-1 testing is available at reference laboratories and at many academic sleep centers.

• Medication interference: Antidepressants, stimulants, and other medications can suppress REM sleep and produce false-negative MSLT results. Ideally, REM-suppressing medications should be tapered at least two weeks before the study, but this must be done safely under medical supervision.
• Insufficient sleep before the MSLT: If the patient does not sleep adequately in the nights leading up to the test, the results may not be valid. Sleep logs or actigraphy for 1–2 weeks before testing help confirm adequate pre-test sleep.
• Misattribution of cataplexy: Cataplexy can be subtle — a brief jaw droop, hand weakness, or knee buckling during laughter — and may not be recognized for what it is. Describing the exact trigger (emotion) and the exact experience (loss of muscle tone with preserved consciousness) to the sleep specialist is important.
• Diagnostic delay: The average delay of 8–15 years from symptom onset to diagnosis is a systemic problem. If excessive daytime sleepiness is persistent, not explained by insufficient sleep, and especially if accompanied by cataplexy-like episodes, seek a sleep medicine evaluation promptly.

• Understand the diagnosis. Ask the sleep specialist to explain which type of narcolepsy you have, what the MSLT results showed, and what the treatment plan will be. Write it down or ask permission to record the conversation.
• Start a medication trial. The specialist will typically start with a wakefulness-promoting agent (modafinil or armodafinil) and add cataplexy treatment if needed. Give each medication a fair trial (usually 2–4 weeks) before judging its effect.
• Begin structured sleep hygiene immediately. A consistent bedtime and wake time, planned naps, and caffeine management are not luxuries — they are treatment.
• Address driving safety. Have an honest conversation with the specialist about when and whether it is safe to drive. This is uncomfortable but critical.
• Tell key people. Selectively informing a supervisor, close colleagues, teachers, or family members — as much as you are comfortable — helps them understand what they are seeing and reduces misinterpretation of symptoms.
• Connect with a patient organization. Wake Up Narcolepsy (wakeupnarcolepsy.org) and the Narcolepsy Network (narcolepsynetwork.org) provide support, education, and community.

• What type of narcolepsy do I have, and how confident is the diagnosis?
• What did the MSLT and PSG show specifically?
• Should CSF hypocretin testing be considered in my case?
• What medication are you recommending first, and what side effects should I watch for?
• When can I safely drive?
• Are there clinical trials I should consider, especially the new orexin agonists?
• How often should I follow up, and what should prompt me to contact you sooner?
• Can you recommend workplace or school accommodation resources?

• ☐ Diagnosis confirmed with PSG + MSLT results (or CSF hypocretin if applicable)
• ☐ Type 1 or Type 2 classification clarified
• ☐ Other causes of sleepiness ruled out (sleep apnea, insufficient sleep, thyroid, medications)
• ☐ Medication plan initiated (wakefulness agent; cataplexy treatment if Type 1)
• ☐ Driving safety discussed with specialist — state reporting requirements reviewed
• ☐ Consistent sleep schedule established (including planned naps)
• ☐ Employer/school informed as appropriate; accommodations discussed
• ☐ Records folder started: sleep study reports, medication list, appointment notes
• ☐ Patient organization contacted (Wake Up Narcolepsy, Narcolepsy Network)
• ☐ Follow-up appointment scheduled (typically 4–6 weeks after starting medication)

• Board certification in sleep medicine (by the American Board of Medical Specialties)
• Experience specifically with narcolepsy (not just sleep apnea)
• Willingness to prescribe sodium oxybate and manage REMS program requirements when indicated
• Access to or familiarity with CSF hypocretin testing
• Awareness of current clinical trials, especially the orexin receptor agonist programs
• Availability for questions between appointments (narcolepsy medication adjustments often need guidance)

The AASM (American Academy of Sleep Medicine) maintains a searchable directory of accredited sleep centers at sleepeducation.org. For patients in Utah and the Mountain West, the University of Utah Sleep-Wake Center and Intermountain Health Sleep Centers are the primary regional resources.

Modafinil (Provigil, available generically) and armodafinil (Nuvigil, available generically) are typically the first medications tried. They promote wakefulness without the intense stimulant effect or abuse potential of traditional amphetamines.

• How they work: The exact mechanism is not fully understood but involves dopamine reuptake inhibition and effects on other wake-promoting pathways.
• Dosing: Modafinil 100–400 mg daily (often split: morning and early afternoon doses). Armodafinil 150–250 mg once daily in the morning.
• Common side effects: Headache, nausea, anxiety, insomnia (if taken too late in the day).
• Important warning for women: Modafinil and armodafinil reduce the effectiveness of hormonal contraceptives. Alternative or additional contraception is needed.
• Insurance: Generic versions are available and generally well-covered.

The AASM strongly recommends modafinil and conditionally recommends armodafinil for excessive daytime sleepiness in narcolepsy.

Solriamfetol was FDA-approved in March 2019 for excessive daytime sleepiness in narcolepsy. It works by inhibiting the reuptake of both dopamine and norepinephrine.

• Dosing: 75–150 mg once daily in the morning.
• Advantages: Often effective when modafinil provides inadequate wakefulness. Rapid onset, generally well tolerated.
• Common side effects: Headache, nausea, decreased appetite, anxiety, insomnia. Can increase blood pressure and heart rate — monitoring is recommended.
• It does not treat cataplexy. A separate cataplexy medication is needed for Type 1 patients.

Pitolisant was FDA-approved in August 2019 for excessive daytime sleepiness in narcolepsy, with a supplemental approval in October 2020 for cataplexy. It is a first-in-class histamine 3 (H3) receptor inverse agonist/antagonist — it promotes wakefulness by enhancing brain histamine release.

• Dosing: Started at 8.9 mg daily, titrated up to 17.8 mg or 35.6 mg based on response.
• Advantages: Non-stimulant, non-scheduled (no DEA controlled substance restrictions), treats both sleepiness AND cataplexy in a single oral medication.
• Common side effects: Insomnia, headache, nausea.
• Important: It has significant drug interactions (CYP2D6 and CYP3A4). Review all medications with the prescriber.

Amphetamine-based stimulants (dextroamphetamine, mixed amphetamine salts, methylphenidate) are still used when first-line agents are insufficient, but they carry greater risks:

• Higher abuse and dependence potential (Schedule II controlled substances)
• More cardiovascular side effects (elevated heart rate and blood pressure)
• Tolerance can develop, requiring dose escalation
• Side effects include anxiety, irritability, appetite suppression, and insomnia

They remain an important option for patients with refractory sleepiness, but their use requires careful monitoring and should be managed by a sleep medicine specialist experienced with narcolepsy.

Certain antidepressants suppress REM sleep and reduce cataplexy frequency. They are used off-label for this purpose (they are not FDA-approved specifically for cataplexy, but their use is well-established in practice):

• Venlafaxine (Effexor) — the most commonly used; an SNRI. Doses for cataplexy are often lower than for depression (37.5–150 mg daily).
• Fluoxetine, citalopram, sertraline (SSRIs) — also effective for cataplexy suppression.
• Clomipramine (tricyclic) — historically effective but more side effects; used less often now.

Critical warning: Abruptly stopping antidepressants used for cataplexy can cause severe rebound cataplexy (status cataplecticus) — near-continuous cataplexy episodes that can be disabling. Any discontinuation must be gradual and medically supervised.

Pitolisant (Wakix) received FDA approval for cataplexy in October 2020, making it the only oral non-controlled medication with dual FDA approval for both excessive daytime sleepiness and cataplexy in narcolepsy. This can simplify treatment for some Type 1 patients.

• Know your triggers. For most people, laughter is the strongest trigger, but surprise, anger, and excitement can also provoke episodes.
• Emotional suppression (avoiding laughter or strong emotions) is a common but harmful coping mechanism. Effective medication should allow normal emotional expression.
• Carry an identification card or wear a medical alert bracelet explaining cataplexy, so bystanders do not mistake an episode for a seizure or cardiac event.
• Position yourself safely when you feel an episode coming — sit down, lean against something, or lower yourself to avoid injury from falling.
• Inform close friends, family, and coworkers about what cataplexy looks like and what to do (nothing medical is needed — the episode passes on its own; just ensure safety).

Sodium oxybate is a central nervous system depressant that consolidates nighttime sleep, increases slow-wave sleep, and reduces REM sleep abnormalities. It is taken in two doses: one at bedtime and one 2.5–4 hours later (requiring an alarm to wake for the second dose). Despite this inconvenience, it uniquely improves all core narcolepsy symptoms and next-day wakefulness.

• Xyrem (sodium oxybate) — the original formulation, FDA-approved in 2002. Contains high sodium (1,640 mg per 9 g dose).
• Xywav (calcium, magnesium, potassium, and sodium oxybates) — FDA-approved July 2020. Contains 92% less sodium than Xyrem, reducing cardiovascular concerns for patients on sodium-restricted diets. Same efficacy. This is generally the preferred formulation now.
• Lumryz (sodium oxybate extended-release) — FDA-approved May 2023. The first once-nightly formulation, eliminating the need to wake for a second dose. A significant convenience improvement.

Because sodium oxybate is a form of gamma-hydroxybutyrate (GHB), it is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. This means:

• The prescriber must be enrolled in the REMS program
• The patient must be enrolled and counseled about risks
• The medication is dispensed only through a central specialty pharmacy (not a local pharmacy)
• Shipments arrive by courier, usually monthly

The REMS process can feel bureaucratic, but it is manageable once set up. The prescribing sleep specialist’s office handles most of the paperwork.

Key safety points:

• Never combine sodium oxybate with alcohol, other sedatives, or opioids — this combination can be fatal.
• Do not drive or perform hazardous activities for at least 6 hours after taking the dose.
• Sleep-related complex behaviors (sleepwalking, sleep-eating) can occur, especially at higher doses. Report these immediately.
• Do not stop abruptly — taper under medical supervision to avoid rebound cataplexy and insomnia.

Short, planned naps (15–20 minutes) are often remarkably refreshing for narcolepsy patients and can sustain alertness for 1–3 hours afterward. The AASM recommends scheduled napping as a complement to medication.

• Plan one or two naps at consistent times (e.g., lunchtime and mid-afternoon).
• Set an alarm — naps longer than 20–30 minutes are usually less effective and may cause grogginess.
• Request nap accommodations at work or school (see Workplace Accommodations below).
• Time naps strategically before important activities, meetings, or driving.

• Consistent schedule: Go to bed and wake up at the same time every day, including weekends. This is especially important for narcolepsy because the circadian system is the remaining anchor when orexin signaling is impaired.
• Dark, cool, quiet bedroom: Optimize the sleep environment. Disrupted nighttime sleep is common in narcolepsy, and environmental factors can make it worse.
• Limit caffeine after early afternoon. Caffeine is a useful tool for wakefulness but impairs nighttime sleep if used too late.
• Avoid heavy meals and alcohol near bedtime. Alcohol worsens nighttime sleep disruption and can interact dangerously with sodium oxybate.
• Regular exercise: Physical activity improves alertness and sleep quality. Schedule exercise earlier in the day; vigorous late-evening exercise may disrupt nighttime sleep.

Narcolepsy is associated with an increased risk of obesity, partly due to metabolic effects of orexin deficiency and partly due to reduced physical activity. Weight gain can worsen daytime sleepiness and increase the risk of obstructive sleep apnea, which further degrades sleep quality.

• A balanced diet with regular meals helps maintain energy levels throughout the day.
• Avoid large, carbohydrate-heavy meals, which can exacerbate postprandial sleepiness.
• If weight gain is a concern, discuss it with the medical team — some narcolepsy medications (especially sodium oxybate) may help with weight management as a secondary effect.

• Do not drive until your sleepiness is adequately controlled with treatment. The sleep specialist should explicitly clear you for driving after assessing treatment response.
• State laws regarding narcolepsy and driving vary. Some states require physician reporting; others rely on self-reporting. Know your state’s requirements.
• Even with treatment, take precautions: avoid driving during your sleepiest times, take a nap before longer drives, never drive after alcohol, pull over immediately if you feel sleepy, and consider having a driving companion for long trips.
• Cataplexy triggered while driving can cause loss of vehicle control. If cataplexy is not well-controlled, driving may not be safe regardless of wakefulness medication status.
• Commercial driving licenses (CDL) have stricter requirements. Discuss this with the sleep specialist if relevant.

Narcolepsy is covered under the Americans with Disabilities Act (ADA). Reasonable accommodations may include:

• A private space and time for scheduled naps (15–20 minutes once or twice daily)
• Flexible scheduling to align work demands with the patient’s best alertness periods
• Modified duties to avoid safety-critical tasks during high-sleepiness periods
• Permission to stand or walk during meetings to maintain alertness
• Adjusted performance metrics that account for the condition

The Job Accommodation Network (askjan.org, 800-526-7234) provides free, confidential guidance on workplace accommodations for narcolepsy.

Children and adolescents with narcolepsy are entitled to accommodations under Section 504 of the Rehabilitation Act or an Individualized Education Program (IEP). Common accommodations include:

• Scheduled rest periods during the school day
• Extended time for tests and assignments
• Permission to stand or move during class
• Modified attendance policies for medical appointments
• Reduced homework load if treatment side effects affect evening functioning
• Education of teachers and staff about narcolepsy to prevent misinterpretation of symptoms as laziness or behavioral problems

Depression occurs in 20–30% of narcolepsy patients — roughly double the general population rate. This is driven by the chronic burden of the disease, social isolation, stigma, and possibly by the direct neurological effects of orexin loss on mood-regulating circuits. Anxiety is also common, often related to fear of cataplexy episodes in public, driving concerns, and job security.

Both depression and anxiety are treatable and should be actively addressed. Treatment options include therapy (cognitive behavioral therapy is well-suited), medication (noting that some antidepressants also help cataplexy), and support groups. The sleep specialist should screen for these conditions regularly.

• Narcolepsy can strain relationships when the partner, family, or friends do not understand the biological nature of the sleepiness. Education helps — invite partners to appointments or share resources from Wake Up Narcolepsy.
• Social situations involving laughter can be anxiety-provoking for patients with cataplexy. Effective cataplexy treatment frees patients to engage socially without fear.
• Intimate relationships may be affected by medication timing (especially the sodium oxybate bedtime schedule) and by the emotional and physical effects of the disease. Open communication with partners is important.
• Parenting with narcolepsy presents unique challenges. Support networks, planned naps, and clear medication schedules help manage the demands.

Oveporexton is an oral, selective orexin receptor 2 (OX2R) agonist developed by Takeda. It is the most advanced orexin agonist in development and is closest to FDA approval.

• Phase 3 results (2025): Two pivotal phase 3 studies — FirstLight (NCT06470828, 168 patients) and RadiantLight (NCT06505031, 105 patients) — both met all primary and secondary endpoints with p<0.001 across all doses at 12 weeks. Oveporexton demonstrated significant improvements in excessive daytime sleepiness, cataplexy, and other narcolepsy symptoms compared to placebo.
• FDA status: The FDA has accepted the new drug application and granted priority review. The PDUFA target action date is in Q3 2026.
• Additional trial: A randomized withdrawal study (NCT07363720) is ongoing.
• Published: Phase 2 results were published in the New England Journal of Medicine.

FDA PRIORITY REVIEW — Decision expected Q3 2026.

Alixorexton is a once-daily oral selective OX2R agonist being developed by Alkermes for both narcolepsy Type 1 and Type 2.

• Phase 2 results: The VIBRANCE-1 study (NCT06358950) in narcolepsy Type 1 and the VIBRANCE-2 study (NCT06555783) in narcolepsy Type 2 both showed positive results, with significant improvements in sleepiness and cataplexy.
• Phase 3 program: The Brilliance phase 3 program has been initiated, including Brilliance NT1 Study 302 (NCT07455383) and Brilliance NT2 (NCT07502443).
• Uniquely important for Type 2: Alixorexton is the first orexin agonist to show positive results specifically in narcolepsy Type 2, where the orexin deficiency is less complete. This is a significant development for Type 2 patients who have fewer treatment options.

PHASE 3 — In active phase 3 trials.

E2086 is another oral OX2R agonist in earlier-stage development by Eisai. A phase 1b study (NCT06462404) has been conducted. Eisai presented clinical study results at World Sleep 2025. This is further behind oveporexton and alixorexton but adds to the breadth of the orexin agonist pipeline.

EARLY STAGE — Phase 1b completed.

Current narcolepsy treatments manage symptoms: stimulants promote wakefulness, antidepressants suppress cataplexy, sodium oxybate consolidates nighttime sleep. None addresses the fundamental problem — the absence of orexin signaling. Orexin receptor agonists are the first drugs designed to do exactly that.

If oveporexton receives FDA approval in 2026, followed by alixorexton potentially in 2028–2029, narcolepsy treatment will undergo its most significant transformation since the introduction of sodium oxybate in 2002. Patients and families should be aware of this development and discuss it with their sleep specialist.

The autoimmune destruction of orexin neurons appears to occur over a period of months around symptom onset. Case reports and small studies have explored immunotherapy (intravenous immunoglobulin, corticosteroids, plasmapheresis) given very early in the disease course, with mixed results. Some patients treated within weeks of symptom onset appeared to have stabilized or partially recovered hypocretin levels, while most treated later showed no benefit.

This remains experimental and is not part of standard care. The challenge is that most patients are not diagnosed until years after onset, by which time the orexin neurons are already lost. Earlier diagnosis would be needed to make this approach practical.

EXPERIMENTAL — Not standard of care. Case reports and small series only.

• What type of narcolepsy do I have (Type 1 or Type 2)?
• What did the MSLT and PSG results show? How confident is the diagnosis?
• Should CSF hypocretin testing be done in my case?
• Could HLA-DQB1*06:02 testing be useful?
• Were other causes of sleepiness fully ruled out (sleep apnea, insufficient sleep, thyroid)?
• What medication do you recommend starting with, and why?
• When will it be safe for me to drive?

• What are the realistic expectations for how much this medication will improve my symptoms?
• What side effects should I watch for, and when should I call you?
• Should I try sodium oxybate (Xywav/Lumryz)? Am I a good candidate?
• How will you monitor my response, and how often should I follow up?
• Are there drug interactions I need to know about with my current medications?
• If this medication is not enough, what is the next step?

• What do you think about the orexin receptor agonists (oveporexton, alixorexton)? When might they be available?
• Am I eligible for any current clinical trials?
• If oveporexton is approved, how soon could I potentially switch to it?
• For Type 2 patients: the alixorexton Type 2 trial showed positive results — what does that mean for my future treatment options?

• What is the best nap schedule for me?
• Can you help me with a letter for workplace/school accommodations?
• Are there resources for managing the emotional impact of narcolepsy?
• Should I be screened for depression or anxiety?
• How does narcolepsy affect pregnancy planning and management?
• Can you connect me with other narcolepsy patients or support groups?

• Educate yourself. Understanding that narcolepsy is a neurological disease — not laziness, depression, or a choice — is the foundation. Read this guide, visit wakeupnarcolepsy.org, and attend an appointment with the sleep specialist.
• Cataplexy can be alarming to witness. Know that it is not dangerous, the person is conscious throughout, and the episode will pass in seconds to minutes. Do not try to restrain them — just ensure they are safe from falling.
• Adjust expectations, not standards. The patient may need naps, earlier bedtimes, and medication schedules that shape the household routine. These are medical needs, not preferences.
• Watch for depression. Partners and family members often notice mood changes before the patient does. Gently encourage professional support if needed.

Narcolepsy onset often occurs in childhood or adolescence, a period when academic performance, social development, and identity formation are critical. Parents can:

• Work with the school to establish a 504 plan or IEP (see School Accommodations above).
• Educate teachers, coaches, and school nurses about narcolepsy. Provide written information.
• Protect the child from bullying related to their symptoms — falling asleep in class or having cataplexy episodes can attract ridicule.
• Encourage normal social activities while planning around medication and nap schedules.
• Connect with other families through Wake Up Narcolepsy’s family programs and the Narcolepsy Network’s annual conference.

Living with someone who has narcolepsy creates unique stresses: managing medication schedules, adjusting household routines, worrying about driving safety, and coping with the social stigma of an invisible disability. Caregivers need their own support. Consider family counseling, caregiver support groups (the National Alliance for Caregiving, caregiving.org, has resources), and regular communication with the treatment team.

• Jazz Pharmaceuticals JazzCares — financial assistance for Xyrem and Xywav. 866-997-3688. jazzcares.com
• Lumryz patient support (Avadel/Alkermes) — Lumryz is made by Avadel (acquired by Alkermes in 2026); financial-assistance enrollment is through the Lumryz program (RYZUP), not JazzCares. Confirm current program details with your prescriber or lumryz.com.
• Harmony Biosciences Patient Support — assistance for Wakix (pitolisant). 855-292-5497. wakix.com/getting-wakix
• Axsome Therapeutics — assistance for Sunosi (solriamfetol). 866-493-7867.
• NeedyMeds — database of prescription-assistance programs. 800-503-6897. needymeds.org
• Patient Advocate Foundation — copay relief and case management. 800-532-5274. patientadvocate.org
• HealthWell Foundation — copay assistance. 800-675-8416. healthwellfoundation.org

• Social Security Disability Insurance (SSDI) — narcolepsy can qualify for disability benefits under certain circumstances. Documentation from a sleep specialist is essential. 800-772-1213. ssa.gov
• ADA accommodations — Job Accommodation Network provides free guidance. 800-526-7234. askjan.org
• FMLA — job-protected leave for medical appointments and treatment adjustments. Apply through employer.
• State vocational rehabilitation services — help with job placement, training, and workplace accommodations. Search by state at rsa.ed.gov.

• Wake Up Narcolepsy — education, support, research funding, advocacy. wakeupnarcolepsy.org
• Narcolepsy Network — peer support, annual conference, resources. narcolepsynetwork.org. 888-292-6522
• Project Sleep — awareness, patient stories, Rising Voices of Narcolepsy program. project-sleep.com
• Hypersomnia Foundation — support for narcolepsy and related disorders. hypersomniafoundation.org

The FDA has approved the broadest range of narcolepsy-specific medications: modafinil (1998), sodium oxybate/Xyrem (2002), armodafinil (2007), pitolisant/Wakix (2019 for EDS, 2020 for cataplexy), solriamfetol/Sunosi (2019), Xywav (2020), and Lumryz (2023). Oveporexton (TAK-861) has priority review with a PDUFA target date in Q3 2026. AASM Clinical Practice Guidelines are the primary clinical reference.

Pitolisant (Wakix) was actually approved in Europe before the US (EMA approval 2016). Sodium oxybate (Xyrem) is approved for narcolepsy with cataplexy. Modafinil is approved with restrictions in the EU (narcolepsy only, after risk review in 2011). Solriamfetol (Sunosi) received EMA approval in 2020. Xywav (low-sodium oxybate) is not approved in the EU (it holds only an EU orphan designation for idiopathic hypersomnia); the oxybate marketed in Europe is Xyrem. Access to sodium oxybate varies by country due to different controlled substance regulations. NICE in the UK has technology appraisals covering sodium oxybate and pitolisant.

Japan has contributed significantly to narcolepsy research. Modafinil is approved. Sodium oxybate is not approved in Japan. The Takeda oveporexton (TAK-861) trials were conducted across 19 countries including Japan, and approval filings are expected globally.

Modafinil and sodium oxybate are approved. Pitolisant and solriamfetol have received Health Canada approval. Provincial formulary coverage varies. Patients facing coverage barriers should ask about special access programs or manufacturer patient-support programs.

• Sodium oxybate access: Controlled substance regulations vary significantly. Available with REMS in the US; restricted or unavailable in some countries.
• Modafinil: Broadly approved but the EU restricts its use to narcolepsy only (not shift work or other off-label uses).
• Orexin agonists: Regulatory filings for oveporexton are expected in multiple major markets following the US submission. Timeline for non-US approvals is not yet established.
• Traditional stimulants: Methylphenidate and amphetamines are controlled substances in all jurisdictions, with varying levels of restriction.

• TAK-994 (suvorexant predecessor orexin agonist) HALTED
  Takeda’s earlier orexin agonist TAK-994 showed promising efficacy in narcolepsy Type 1 (NCT04096560, NCT04820842) but was halted due to hepatotoxicity (liver safety concerns). The program was discontinued. TAK-861 (oveporexton) was developed as the successor with a different chemical structure specifically to avoid this toxicity.
• Thyrotropin-releasing hormone (TRH) analogs FAILED
  TRH analogs were investigated for narcolepsy wakefulness promotion. Despite some preclinical promise, clinical results were disappointing, and none reached approval.
• Routine immunotherapy for established narcolepsy NOT EFFECTIVE
  While there is theoretical rationale for immunotherapy very early in the disease course (within weeks of onset), immunotherapy given after the orexin neurons are already destroyed does not restore them. IVIG, corticosteroids, and plasmapheresis have not shown benefit in patients with established narcolepsy. This is not a treatment option for the vast majority of patients who are diagnosed years after onset.
• Pemoline (Cylert) WITHDRAWN
  Pemoline was a CNS stimulant used for narcolepsy that was withdrawn from the US market in 2005 due to hepatotoxicity risk (liver failure). It should not be used.

• AASM — American Academy of Sleep Medicine; the professional organization that sets clinical guidelines for sleep disorders.
• Armodafinil — the R-enantiomer of modafinil; a wakefulness-promoting agent used for narcolepsy EDS.
• Cataplexy — sudden, brief loss of muscle tone triggered by strong emotions (especially laughter); specific to narcolepsy Type 1.
• CSF — cerebrospinal fluid; the fluid surrounding the brain and spinal cord. CSF hypocretin-1 levels help diagnose narcolepsy Type 1.
• EDS — excessive daytime sleepiness; the hallmark symptom of narcolepsy.
• Epworth Sleepiness Scale (ESS) — a standardized questionnaire that measures subjective daytime sleepiness on a scale of 0–24.
• HLA-DQB1*06:02 — a specific genetic variant of the human leukocyte antigen system; present in up to 98% of narcolepsy Type 1 patients.
• Hypnagogic hallucination — vivid sensory experience occurring while falling asleep; caused by REM intrusion into wakefulness.
• Hypnopompic hallucination — vivid sensory experience occurring while waking up.
• Hypocretin — another name for orexin; a neuropeptide critical for sleep-wake regulation. Hypocretin-1 and orexin-A are the same molecule.

• Lateral hypothalamus — the brain region containing the orexin-producing neurons that are destroyed in narcolepsy Type 1.
• Lumbar puncture — a procedure to collect cerebrospinal fluid; used to measure hypocretin-1/orexin-A levels.
• Modafinil — a wakefulness-promoting agent; the most commonly used first-line medication for narcolepsy EDS.
• MSLT — Multiple Sleep Latency Test; the gold standard diagnostic test for narcolepsy, measuring how quickly a person falls asleep and whether REM sleep occurs abnormally early.
• Narcolepsy Type 1 (NT1) — narcolepsy with cataplexy and/or low CSF hypocretin-1; caused by orexin neuron loss.
• Narcolepsy Type 2 (NT2) — narcolepsy without cataplexy; mechanism less understood.
• Orexin — neuropeptide produced in the lateral hypothalamus that stabilizes sleep-wake boundaries. Also called hypocretin.
• Orexin receptor agonist — a drug that activates orexin receptors, mimicking the effect of natural orexin. The first drugs to address the root cause of narcolepsy Type 1.
• OX2R — orexin receptor type 2; the primary target of emerging orexin agonist drugs.
• Pitolisant — histamine H3 receptor inverse agonist; FDA-approved for both EDS and cataplexy in narcolepsy.
• Polysomnogram (PSG) — overnight sleep study monitoring brain waves, breathing, and movement; the prerequisite for the MSLT.

• REM sleep — rapid eye movement sleep; the sleep stage associated with vivid dreaming. In narcolepsy, REM intrudes inappropriately into wakefulness.
• REMS program — Risk Evaluation and Mitigation Strategy; a safety program required for sodium oxybate distribution.
• Sleep-onset REM period (SOREMP) — REM sleep occurring within 15 minutes of sleep onset; a diagnostic marker for narcolepsy on the MSLT.
• Sleep paralysis — temporary inability to move or speak while falling asleep or waking up; caused by REM atonia persisting into wakefulness.
• Sodium oxybate — the active ingredient in Xyrem, Xywav, and Lumryz; treats EDS, cataplexy, and disrupted nighttime sleep.
• Solriamfetol — dopamine/norepinephrine reuptake inhibitor; FDA-approved for EDS in narcolepsy.
• Status cataplecticus — near-continuous cataplexy episodes; can occur with abrupt discontinuation of cataplexy medications.

Guidelines:

• AASM Clinical Practice Guidelines for the Treatment of Central Disorders of Hypersomnolence
• International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR)
• European Academy of Neurology / European Sleep Research Society Guidelines on the Management of Narcolepsy

Key studies and trials referenced in this guide:

• Wake Up Narcolepsy (wakeupnarcolepsy.org) — Education, research funding, advocacy, and patient support
• Narcolepsy Network (narcolepsynetwork.org) — Peer support, annual conference, resources. 888-292-6522
• Project Sleep (project-sleep.com) — Awareness, patient stories, advocacy
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials
• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
• AASM Sleep Education (sleepeducation.org) — Patient-facing sleep information and sleep center directory
• Hypersomnia Foundation (hypersomniafoundation.org) — Support for narcolepsy and related disorders